Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Anti-IL6R and Anticoagulation Therapy Improves Prognosis in Patients With Advanced Nasopharyngeal Carcinoma

NCT06442709 is registered in ClinicalTrials.gov with Affiliated Hospital of Nantong University as lead sponsor.

NCT NCT06442709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06442709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Anti-IL6R and Anticoagulation Therapy Improves Prognosis in Patients With Advanced Nasopharyngeal Carcinoma
Lead sponsor
Affiliated Hospital of Nantong University
Phase
Not applicable
Overall status
Unknown status
Start date
August 1, 2021
Completion date
July 1, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma